Rofecoxib and celecoxib demonstrate similar, significant 6-week efficacy vs placebo in OA treatment
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studiesCurr Med Res Opin. 2006 Jan;22(1):199-210
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
808 patients, combined from two trials, with knee osteoarthritis were randomized to receive either celecoxib 200mg daily, rofecoxib 12.5mg daily, or placebo. Patients were assessed over a 6-week period of treatment on a Patient Global Assessment of Response to Therapy (PGART), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and Physical Function subscales, and the i...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE